AMG 837 calcium hydrate

Name: AMG 837 calcium hydrate
Brand: MedChemExpress
SKU: HY-13967B
Rating: 5.0 (3 reviews)

Cat. No.: HY-13967B Purity: 99.00%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

AMG 837 calcium hydrate is an orally active, selective GPR40/FFA1 agonist with an EC₅₀ of 1.5 nM against human GPR40. AMG 837 calcium hydrate stimulates insulin secretion in a glucose-dependent manner, and effectively improves glycemic control in both normal and diabetic rodent models. AMG 837 calcium hydrate binds to the BacA protein and impairs the survival and replication of Brucella. AMG 837 calcium hydrate can be used in research related to type 2 diabetes and brucellosis.

For research use only. We do not sell to patients.

CAS No. : 1259389-38-2

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Other Forms of AMG 837 calcium hydrate:

AMG 837 In-stock
AMG 837 hemicalcium Get quote
AMG 837 sodium salt Get quote

3 Publications Citing Use of MCE AMG 837 calcium hydrate

Cell Imaging/Staining

: AMG 837 calcium hydrate purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2025 Apr 9:757:151624. [Abstract]; Ability of different concentrations compounds or drugs (GM, Gentamicin, Sterile; AMG 837; RORγt 13; RIF; 4, 16 μg/mL) to clear B. melitensis TZ in RAW264.7 cells at 24 h. Cells appear blue; B. melitensis TZ appear green.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Free Fatty Acid Receptor Isoform Specific Products:

View All Isoforms

FFAR1 FFAR2 FFAR3 FFAR4

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

pIC50: 8.13 (FFA1)^[3]

In Vitro

AMG 837 calcium hydrate stimulates inositol phosphate accumulation in A9_GPR40 cells with an EC₅₀ of 7.8 nM^[1].
AMG 837 calcium hydrate potently and selectively stimulates Ca²⁺ influx mediated by human GPR40 in CHO cells, with an EC₅₀ of 13.5 nM, and shows no activity against the homologous human GPR41, GPR43 or GPR120 receptors^[1].
AMG 837 calcium hydrate activates GPR40 across multiple preclinical species, with EC₅₀ values of 22.6 nM in mice, 31.7 nM in rats, 71.3 nM in dogs, and 30.6 nM in rhesus monkeys in the CHO cell aequorin assay^[1].
The potency of AMG 837 calcium hydrate against human GPR40 decreases in the presence of serum albumin or human serum, with an EC₅₀ value of 210 nM in 0.625% HSA and 2140 nM in 100% human serum^[1].
AMG 837 (1 μM) calcium hydrate enhances insulin secretion activity of primary mouse islets in a glucose-dependent manner^[1].
AMG 837 calcium hydrate inhibits the growth of B. melitensis TZ, B. melitensis M5-90, B. suis S2, and B. abortus A19^[2].
AMG 837 (4-16 μg/mL; 6-48 h) calcium hydrate effectively inhibits B. melitensis TZ in RAW264.7 cells at a concentration of 4 μg/mL, and completely eliminates the bacterium at 16 μg/mL following 6, 12, 24, and 48 h of incubation^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

AMG 837 (0.03-0.3 mg/kg; p.o.; single administration) calcium hydrate improves glucose tolerance in a dose-dependent manner in normal Sprague-Dawley rats^[1].
AMG 837 (0.3 mg/kg; p.o.; single administration) calcium hydrate effectively improves glucose tolerance and increases glucose-stimulated insulin secretion in normal Sprague-Dawley rats even after two consecutive glucose challenges^[1].
AMG 837 (0.3-3 mg/kg; p.o.; single administration) calcium hydrate reduces the postprandial blood glucose AUC_0-t by approximately 46% in insulin-resistant Zucker obese rats by enhancing glucose-stimulated insulin secretion^[1].
AMG 837 (0.03-0.3 mg/kg; p.o.; once daily for 21 days) calcium hydrate maintains the efficacy of improving glucose tolerance in insulin-resistant Zucker obese rats, and reduces glucose AUC_0-t by 25% at the dose of 0.3 mg/kg on day 21 of administration; its mechanism of action is to continuously stimulate insulin secretion via glucose, without affecting the body weight of rats^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley (8-week-old male)^[1]
Dosage:	0.03, 0.1, 0.3 mg/kg
Administration:	p.o.; single dose
Result:	Did not affect baseline glucose levels 30 minutes post-dose. Induced a dose-dependent increase in plasma insulin levels, with peak secretion at 5 and 15 minutes post-glucose challenge. Achieved a half-maximal dose to lower post-prandial glucose of approximately 0.05 mg/kg.

Animal Model:	Sprague-Dawley (8-week-old male)^[1]
Dosage:	0.3 mg/kg
Administration:	p.o.; single dose
Result:	Improved blood glucose levels during both glucose challenges, with reduced glucose AUC during each challenge. Induced peak insulin secretion soon after each glucose administration, mirroring the single-challenge response.

Animal Model:	Zucker fatty (fa/fa) (8-week-old male; insulin-resistant, impaired glucose tolerance model)^[1]
Dosage:	0.03, 0.1, 0.3 mg/kg
Administration:	p.o.; single dose
Result:	Caused baseline glucose levels to trend lower and insulin levels to trend higher 30 minutes post-dose, though neither reached statistical significance. Reduced post-glucose challenge glucose levels at all doses, with glucose AUC reduced by ~46% for all doses. Induced a spike in plasma insulin levels 5 and 15 minutes post-glucose challenge at all doses.

Animal Model:	Zucker fatty (fa/fa) (8-week-old male; insulin-resistant, impaired glucose tolerance model)^[1]
Dosage:	0.03, 0.1, 0.3 mg/kg
Administration:	p.o.; daily; 21 days
Result:	On day 1, reduced glucose AUC by 17%, 34% , and 39% at 0.03, 0.1, and 0.3 mg/kg doses, respectively, with corresponding increased insulin secretion post-glucose challenge. On day 21, reduced glucose AUC by 7%, 15%, and 25% at 0.03, 0.1, and 0.3 mg/kg doses, respectively, with increased insulin secretion in the mid- and high-dose groups post-glucose challenge. Caused no differences in body weight between treatment and control groups over the 21-day period.

Molecular Weight

455.45

Formula

C₂₆H₂₁F₃O₃.1/2Ca.H₂O

CAS No.

1259389-38-2

Appearance

Solid

Color

White to off-white

SMILES

OC(C[C@H](C#CC)C(C=C1)=CC=C1OCC2=CC=CC(C3=CC=C(C=C3)C(F)(F)F)=C2)=O.[Ca].O.[1/2]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : ≥ 42 mg/mL (92.22 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.1956 mL	10.9782 mL	21.9563 mL
5 mM	0.4391 mL	2.1956 mL	4.3913 mL
10 mM	0.2196 mL	1.0978 mL	2.1956 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (5.49 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.49 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.49 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.00%

Select Batch:

Data Sheet (280 KB) SDS (252 KB)

COA (248 KB) HNMR (144 KB) LCMS (95 KB)

Handling Instructions (2659 KB)

References

[1]. Lin DC, et al. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS One. 2011;6(11):e27270.
[Content Brief]

[2]. Guo KX, et al. High-throughput screening unveils AMG 837 and RORγt 13 as the potent Brucella inhibitor by targeting BacA. Biochem Biophys Res Commun. 2025;757:151624. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.1956 mL	10.9782 mL	21.9563 mL	54.8908 mL
	5 mM	0.4391 mL	2.1956 mL	4.3913 mL	10.9782 mL
	10 mM	0.2196 mL	1.0978 mL	2.1956 mL	5.4891 mL
	15 mM	0.1464 mL	0.7319 mL	1.4638 mL	3.6594 mL
	20 mM	0.1098 mL	0.5489 mL	1.0978 mL	2.7445 mL
	25 mM	0.0878 mL	0.4391 mL	0.8783 mL	2.1956 mL
	30 mM	0.0732 mL	0.3659 mL	0.7319 mL	1.8297 mL
	40 mM	0.0549 mL	0.2745 mL	0.5489 mL	1.3723 mL
	50 mM	0.0439 mL	0.2196 mL	0.4391 mL	1.0978 mL
	60 mM	0.0366 mL	0.1830 mL	0.3659 mL	0.9148 mL
	80 mM	0.0274 mL	0.1372 mL	0.2745 mL	0.6861 mL